Pazopanib for treatment of patients with advanced renal cell carcinoma

Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma: a single technology appraisal

Kidney cancer caused 3,848 deaths in the UK in 2008. It is the seventh most common cancer in men; 5,165 new cases were diagnosed in 2007. Until 2009 the only licensed treatments available to NHS patients with metastatic kidney cancer were IFN and interleukin-2. The benefits of these are believed to be modest. Pazopanib hydrochloride (GlaxoSmithKline) is an oral multi-targeted kinase receptor inhibitor with anti-tumour activity. Pazopanib inhibits vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3, platelet-derived growth factor receptor (PDGFR), and c-kit, which may result in inhibition of angiogenesis in tumours in which these receptors are upregulated.

Outcome and Translation

Following this appraisal, NICE recommended pazopanib as a possible first-line treatment for some people with advanced renal cell carcinoma: www.nice.org.uk/guidance/TA215.

HERU researchers involved in this research project: Mary Kilonzo (HERU) and Luke Vale (HERU/HSRU)

External Collaborators: J Hislop, A Elders, C Fraser, G Mowatt (HSRU, University of Aberdeen); D Bissett (Department of Clinical Oncology, Aberdeen Royal Infirmary) and S McClinton (Department of Urology Aberdeen Royal Infirmary).

Publications

Kilonzo, M., Hislop, J., Elders, A., Fraser, C., Bissett, D., McClinton, S., Mowatt, G. and Vale, L. (2010) Pazopanib for the first line treatment of patients with advanced and/or metastatic renal cell carcinoma: a single technology appraisal. Report submitted to NICE, National Institute for Healthcare and Excellence.

Kilonzo, M., Hislop, J., Elders, A., Fraser, C., Bissett, D., McClinton, S., Mowatt, G. and Vale, L. (2012) Pazopanib for the first line treatment of patients with advanced and/or metastatic renal cell carcinoma: a single technology appraisal, NETSCC: Aberdeen Health Technology Assessment Group, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.

Kilonzo, M., Hislop, J., Elders, A., Fraser, C., Bissett, D., McClinton, S., Mowatt, G. and Vale, L. (2013) 'Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal', Pharmacoeconomics, 31(1), 15-24.